The National Company Law Tribunal (NCLT) has approved the merger of SeQuent Scientific with Viyash Life Sciences in a deal valued at around ₹8,000 crore. The move brings together SeQuent’s animal-health business and Viyash’s pharmaceutical manufacturing capabilities under one larger platform.
As part of the merger, Viyash shareholders will receive 56 SeQuent shares for every 100 shares they hold. Viyash founder Hari Babu Bodepudi is expected to lead the combined entity as CEO once the integration is complete.
The merged company will have a wider global presence, operating across more than 150 countries. It will also benefit from a bigger research and development base and a significantly larger number of US FDA-approved manufacturing facilities.
The consolidation is aimed at improving profitability, strengthening the balance sheet, and unlocking cost efficiencies through shared procurement, operations and scaled-up production. The companies expect the integration to accelerate growth in both animal-health and human-health segments.
Also Read: NHAI opens public investment route for national highways